People

Activaero has hired Christian Pangratz as its new Chief Business Officer, replacing Henrik Luessen. Pangratz comes to Activaero from Nektar, where he served as Executive Director of Business Development. Luessen will continue to work with the company part time while focusing the majority of his efforts on his consulting firm. Pangratz will be responsible for … [Read more...] about Activaero announces new Chief Business Officer

Chuck Bramlage has been appointed President and Chief Executive Officer of Pearl Therapeutics, replacing interim President and CEO Howard Rosen. Pearl, a California pharmaceutical company developing inhaled treatments for COPD and asthma, was founded in 2006. Its lead product, PT 003, a LAMA/LABA combination MDI, is moving into Phase 2b trials. Bramlage was most … [Read more...] about Pearl Therapeutics announces new President and CEO

Scott R. Ward has been named Chairman of the Board of Directors by MAP Pharmaceuticals, replacing Staven A. Elms. MAP plans to submit an NDA for its Levadex inhaled ergotamine for the treatment of migraine headaches within the next few months. Read the company's press release. … [Read more...] about MAP Pharmaceuticals appoints new board chair

CMO PharmaForm, a wholly-owned subsidiary of Akela Pharma, has hired J. Blair West, formerly of Bend Research and Azo Pharma, as Vice President of Pharmaceutical Operations. In addition, the company says, Feng Zhang will become Senior Formulation Consultant. PharmaForm provides formulation and manufacturing services for a number of dosage forms, including dry … [Read more...] about PharmaForm announces new hires

Patrick G. LePore, President, CEO, and Chair of Par Pharmaceuticals will temporarily take over the reins at the company's subsidiary Strativa Pharmaceuticals after Strativa's President John A. MacPhee resigned. MacPhee was also Executive VP of Par. Strativa's products include Nascobal cyanocobalamin nasal spray. Read the company's press release. … [Read more...] about Strativa president John A. MacPhee resigns

William M. Wells has resigned as Chairman of the Board of Valeant Pharmaceuticals and has been replaced by Robert A. Ingram. Valeant subsidiary Biovail is co-devloping the Staccato loxapine inhaler with Alexza Pharmaceuticals. The FDA issued a complete response letter for Staccato loxapine in October 2010. The announcement comes less than two weeks after Elan … [Read more...] about Robert A. Ingram appointed Chairman of Valeant Board

Richard Hawkins, who founded Pharmaco, now PPD Development, has joined the board of directors of Texas-based inhalation drug development company Savara. The company is developing a number of dry powder aerosol medicines based on its NanoCluster particle manufacturing technology. Read the company's press release. … [Read more...] about Savara appoints Richard Hawkins to board

Thomas P. McCracken has joined MAP Pharmaceuticals as Vice President, Intellectual Property. MAP's lead candidate, Levadex inhaled dihydroergotamine, is in Phase 3 trials, and McCracken will be responsible for the intellectual property program in support of its planned commercialization, according to the company. Read the MAP Pharmaceutical press release. … [Read more...] about MAP Pharmaceuticals appoints Thomas P. McCracken